This is a preview of subscription content, log in via an institution to check access.
Reference
European Medicines Agency (EMA). Use of multiple sclerosis medicine Lemtrada restricted while EMA review is ongoing. Internet Document : 12 Apr 2019. Available from: URL: https://www.ema.europa.eu/en/news/use-multiple-sclerosis-medicine-lemtrada-restricted-while-ema-review-ongoing
Rights and permissions
About this article
Cite this article
EMA requires restricted use while reviewing alemtuzumab. Reactions Weekly 1750, 1 (2019). https://doi.org/10.1007/s40278-019-60865-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-019-60865-7